Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 6/2002

01-08-2002

A comprehensive worksite cancer prevention intervention: behavior change results from a randomized controlled trial (United States)

Authors: Glorian Sorensen, Anne M Stoddard, Anthony D. LaMontagne, Karen Emmons, Mary Kay Hunt, Richard Youngstrom, Deborah McLellan, David C Christiani

Published in: Cancer Causes & Control | Issue 6/2002

Login to get access
Metadata
Title
A comprehensive worksite cancer prevention intervention: behavior change results from a randomized controlled trial (United States)
Authors
Glorian Sorensen
Anne M Stoddard
Anthony D. LaMontagne
Karen Emmons
Mary Kay Hunt
Richard Youngstrom
Deborah McLellan
David C Christiani
Publication date
01-08-2002
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 6/2002
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1023/A:1016385001695

Other articles of this Issue 6/2002

Cancer Causes & Control 6/2002 Go to the issue

Editorial Board

Disseminating research findings into public health practice

OriginalPaper

GSTM-1 and NAT2 and genetic alterations in colon tumors

OriginalPaper

Aspirin, other NSAIDs, and ovarian cancer risk (United States)

OriginalPaper

Breast cancer survival in African American women: Is alcohol consumption a prognostic indicator?

Editorial Commentary

In-utero exposures and breast cancer risk: joint effect of estrogens and insulin-like growth factor?

OriginalPaper

Animal-related occupations and the risk of leukemia, myeloma, and non-Hodgkin's lymphoma in Canada
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits